Altmetric

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

File Description SizeFormat 
THELANCETRM-D-17-00054.pdfAccepted version1.02 MBAdobe PDFView/Open
Title: Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Authors: Herazo-Maya, JD
Sun, J
Molyneaux, PL
Li, Q
Villalba, JA
Tzouvelekis, A
Lynn, H
Juan-Guardela, BM
Risquez, C
Osorio, JC
Yan, X
Michel, G
Aurelien, N
Lindell, KO
Klesen, MJ
Moffatt, MF
Cookson, WO
Zhang, Y
Garcia, JGN
Noth, I
Prasse, A
Bar-Joseph, Z
Gibson, KF
Zhao, H
Herzog, EL
Rosas, IO
Maher, TM
Kaminski, N
Item Type: Journal Article
Abstract: BACKGROUND: The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable. Clinical prediction tools are not accurate enough to predict disease outcomes. METHODS: We enrolled patients with IPF diagnosis in a six-cohort study at Yale University (New Haven, CT, USA), Imperial College London (London, UK), University of Chicago (Chicago, IL, USA), University of Pittsburgh (Pittsburgh, PA, USA), University of Freiburg (Freiburg im Breisgau, Germany), and Brigham and Women's Hospital-Harvard Medical School (Boston, MA, USA). Peripheral blood mononuclear cells or whole blood were collected at baseline from 425 participants and from 98 patients (23%) during 4-6 years' follow-up. A 52-gene signature was measured by the nCounter analysis system in four cohorts and extracted from microarray data (GeneChip) in the other two. We used the Scoring Algorithm for Molecular Subphenotypes (SAMS) to classify patients into low-risk or high-risk groups based on the 52-gene signature. We studied mortality with a competing risk model and transplant-free survival with a Cox proportional hazards model. We analysed timecourse data and response to antifibrotic drugs with linear mixed effect models. FINDINGS: The application of SAMS to the 52-gene signature identified two groups of patients with IPF (low-risk and high-risk), with significant differences in mortality or transplant-free survival in each of the six cohorts (hazard ratio [HR] range 2·03-4·37). Pooled data showed similar results for mortality (HR 2·18, 95% CI 1·53-3·09; p<0·0001) or transplant-free survival (2·04, 1·52-2·74; p<0·0001). Adding 52-gene risk profiles to the Gender, Age, and Physiology index significantly improved its mortality predictive accuracy. Temporal changes in SAMS scores were associated with changes in forced vital capacity (FVC) in two cohorts. Untreated patients did not shift their risk profile over time. A simultaneous increase in up score and decrease in down score was predictive of decreased transplant-free survival (3·18, 1·16-8·76; p=0·025) in the Pittsburgh cohort. A simultaneous decrease in up score and increase in down score after initiation of antifibrotic drugs was associated with a significant (p=0·0050) improvement in FVC in the Yale cohort. INTERPRETATION: The peripheral blood 52-gene expression signature is predictive of outcome in patients with IPF. The potential value of the 52-gene signature in predicting response to therapy should be determined in prospective studies. FUNDING: The Pulmonary Fibrosis Foundation, the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, and the National Heart, Lung, and Blood Institute of the US National Institutes of Health.
Issue Date: 1-Nov-2017
Date of Acceptance: 16-Aug-2017
URI: http://hdl.handle.net/10044/1/62741
DOI: https://dx.doi.org/10.1016/S2213-2600(17)30349-1
ISSN: 2213-2600
Publisher: Elsevier
Start Page: 857
End Page: 868
Journal / Book Title: Lancet Respiratory Medicine
Volume: 5
Issue: 11
Copyright Statement: © 2017 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Medical Research Council (MRC)
Royal Brompton & Harefield NHS Foundation Trust
Medical Research Council (MRC)
National Institute for Health Research
Funder's Grant Number: G1000758
B0479
G1000758
CS-2013-13-017
Keywords: Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
Respiratory System
General & Internal Medicine
FORCED VITAL CAPACITY
PROGNOSTIC VALUE
MAST-CELLS
SURVIVAL
MORTALITY
PROTEIN
SERUM
POLYMORPHISM
ASSOCIATION
EXPRESSION
Aged
Cohort Studies
Female
Gene Expression Profiling
Genetic Markers
Genetic Testing
Humans
Idiopathic Pulmonary Fibrosis
Leukocytes, Mononuclear
Linear Models
Male
Middle Aged
Oligonucleotide Array Sequence Analysis
Prognosis
Proportional Hazards Models
Risk Assessment
Risk Factors
Time Factors
Vital Capacity
Publication Status: Published
Online Publication Date: 2017-09-21
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons